Sheng Iris Y, Ornstein Moshe C
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Center Institute, Cleveland, OH, USA.
Cancer Manag Res. 2020 Jun 23;12:4871-4881. doi: 10.2147/CMAR.S202017. eCollection 2020.
Immunotherapy has revolutionized the management of metastatic renal cell carcinoma with four checkpoint inhibitors (nivolumab, ipilimumab, avelumab, and pembrolizumab) approved either as monotherapy or as combination therapy. The use of ipilimumab and nivolumab for treatment-naïve, intermediate to poor risk, metastatic renal cell carcinoma was the first checkpoint inhibitor-based combination therapy and remains the only dual checkpoint inhibitor combination approved in mRCC. In this article, we review the trials that led to the approval of ipilimumab and nivolumab in this setting. We also highlight the ongoing trials using this combination, its use in special populations, and clinically relevant unanswered questions.
免疫疗法彻底改变了转移性肾细胞癌的治疗方式，四种检查点抑制剂（纳武单抗、伊匹单抗、阿维鲁单抗和帕博利珠单抗）已获批用于单药治疗或联合治疗。伊匹单抗和纳武单抗用于初治、中低风险的转移性肾细胞癌，这是首个基于检查点抑制剂的联合疗法，并且仍然是转移性肾细胞癌中唯一获批的双检查点抑制剂联合疗法。在本文中，我们回顾了使伊匹单抗和纳武单抗在此情况下获批的试验。我们还强调了正在进行的使用该联合疗法的试验、其在特殊人群中的应用以及临床上尚未解答的相关问题。
